Company Overview
| Company Name | Nihon Science Innovation and Solutions Co., Ltd. (NSiS) |
|---|---|
| Established | April 30, 2025 |
| Headquarters | Yaesu Central Tower 7F, Tokyo Midtown Yaesu, 2-2-1 Yaesu, Chuo-ku, Tokyo 104-0028, Japan |
| Representative | Noriaki Kitamura, PhD, MBA — President & CEO |
| Capital | JPY 30 million (as of September 2026), plus JPY 10 million in capital reserve |
| Business Overview | Research, development, manufacturing, and commercialization of fully human proteins |
| Core Technology | Fully human protein production technology based on Japanese Patent No. 7645562 |
| R&D Base | Partners Laboratory, National Cancer Center Research Institute, Japan |
Key Achievements
Public Grant Awards
Total: JPY 52.4 million (Grant reimbursement claims to be submitted by March 2027)
| Grant Program | Award Details |
|---|---|
| Monozukuri Subsidy – Global Expansion Category | Selected on July 28, 2025 (maximum grant: JPY 30 million) |
| Tokyo Metropolitan Government Startup Grant | Selected on September 1, 2025 (maximum grant: JPY 4 million) |
| New Product and New Business Development Grant | Selected on November 1, 2025 (JPY 18.4 million) |
Selection for International Events
Selected by JETRO to participate in the Japan Pavilion at:
- BIO International Convention (2026)
- BIO-Europe (2026)
Relocation of R&D Base to the National Cancer Center
Following a review by the National Cancer Center Japan, NSiS received approval in August 2026 to move into the Partners Laboratory and began R&D operations there in October 2026.